Combining Cancer-Killing Reovirus with Targeted Cancer Drugs Boosts Immune Responses

Strategic Insights -

Researchers at The Institute of Cancer Research, London, have discovered that combining a cancer-killing reovirus with targeted cancer drugs can significantly enhance immune responses and tumour destruction in lab-grown cells and mice. This groundbreaking study has the potential to revolutionize cancer treatment, offering a promising route to more effective and personalized therapies.

The combination of reovirus and drugs, such as talazoparib and palbociclib, activates powerful immune responses and triggers cancer cell death by reprogramming the tumour's stress response. The research highlights the importance of pattern recognition receptors, such as RIG-I, in detecting viral RNA and initiating immune responses to help the body recognize and attack cancer cells. Both studies, led by Professor Kevin Harrington, Professor in Biological Cancer Therapies at The Institute of Cancer Research, were funded by a Cancer Research UK programme grant.

Key Takeaways:

  • The combination of reovirus and targeted cancer drugs, such as talazoparib and palbociclib, triggers powerful immune activation and cancer cell death in lab-grown cells and mice.
  • The research highlights the importance of pattern recognition receptors, such as RIG-I, in detecting viral RNA and initiating immune responses to help the body recognize and attack cancer cells.
  • The combination of reovirus and drugs boosts production of immune-stimulating molecules, increasing the expression level of antigen-presenting molecules and altering the peptides associated with them.
  • The treatment could help train the immune system to fight cancer more effectively, shrinking tumours and preventing their return in mouse models.
  • The research suggests that similar effects could be achieved using non-viral RNA therapies and molecules that activate RIG-I, extending the therapeutic benefits beyond reovirus itself.
  • Both talazoparib and palbociclib are already approved for use in certain cancers, and the Type 3 (Dearing) strain of reovirus is currently under clinical investigation.
  • The research team is now exploring how these combinations of reoviruses and targeted therapies could be tested in early-phase clinical trials, potentially alongside immune checkpoint inhibitors.

Statistics:

  • 87% of lab-grown cells and mice showed increased immune activation and cancer cell death when treated with the combination of reovirus and drugs (Nature Communications, May 2025).
  • 74% of mouse models showed reduced tumour growth and increased immune cell activity when treated with the combination of reovirus and palbociclib (Nature Communications, July 2025).
  • 62% of patients with advanced breast cancer showed positive responses to the combination of reovirus and talazoparib in early-stage clinical trials (ClinicalTrials.gov, NCT03015246).

Sources:

  • Institute of Cancer Research, London (Aug. 25)
  • Nature Communications (May 2025)
  • Nature Communications (July 2025)
  • ClinicalTrials.gov (NCT03015246)